• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA grants orphan drug status to ARB1002 for pancreatic cancer

by Marisa Wexler, MS | Jan 9, 2026 | Myeloma News

A new experimental treatment for pancreatic cancer, ARB1002, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is expected to enter early clinical testing later this year. The FDA reserves this status for treatments...

Is Less “Sufficient” and “Safe” in the MRD Era – Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma

by MM360 Staff | Jan 9, 2026 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Preclinical study shows RNA therapy halts glioblastoma growth

by Marisa Wexler, MS | Jan 8, 2026 | Myeloma News

TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of glioblastoma. That’s according to the study, “Nanotherapy Targeting miR-10b Improves Survival in...

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

by MM360 Staff | Jan 8, 2026 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Ernexa’s stem cell therapy could soon enter ovarian cancer trials

by Marisa Wexler, MS | Jan 7, 2026 | Myeloma News

Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S. Food and Drug Administration (FDA) at a recent meeting “provided strong regulatory alignment on Ernexa’s development...
« Older Entries
Next Entries »

Recent Content

  • Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
  • CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT